MAPT and Alzheimer disease: It leads to progressive cognitive impairment and neuropathological alterations that closely resemble those observed in AD patients, including increased in Aβ protein, Tau hyperphosphorylation, increased oxidative stress and marked neuroinflammation and neurodegeneration (Knezovic et al., 2015; Grieb, 2016; de la Monte, 2017; Moreira-Silva et al., 2018; Amani et al., 2019; Voronkov et al., 2019).